Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Vicore Pharma to Present at Upcoming Investor Conferences

Vicore Pharma Holding

Stockholm, February 26, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following investor conferences:

  • TD Cowen 46th Annual Health Care Conference
    Location: Boston, USA
    Format: Presentation and 1×1 meetings
    Presentation Date and Time: Wednesday, March 4 at 1:50 PM EST
    Webcast: Link
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • Leerink Partners Global Healthcare Conference 2026
    Location: Miami, USA
    Format: Presentation and 1×1 meetings
    Presentation Date and Time: Monday, March 9 at 11:20 AM EST
    Webcast: Link
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • 2026 Jefferies Biotech on the Beach Summit
    Location: Miami, USA
    Format: 1×1 meetings
    Date: Tuesday, March 10
    Participants: Ahmed Mousa, CEO, and Megan Richards, VP of IR and Comms
  • Sweden Life Science Day 2026
    Location: Gothenburg, Sweden
    Format: Presentation
    Presentation Date and Time: Wednesday, March 4 at 9:15 AM CET
    Participant: Hans Jeppsson, CFO

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma 
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.
 
Vicore is publicly listed on the Nasdaq Stockholm exchange with the ticker VICO. www.vicorepharma.com

Attachments
Vicore Pharma to Present at Upcoming Investor Conferences

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.